Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
  • Clinical Data

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

BioSpace

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology's annual conference but its biggest data are expected later this year.

Oncology

Read full story

pharminent June 2, 2026 (Last updated: June 3, 2026)

BioSpace

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.

Oncology

Read full story

Post navigation

Previous: FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
Next: ASCO26: In vivo oncology approaches continue to show promise

Related Stories

  • Clinical Data

Novo Nordisk starts trialing lower maintenance doses of oral Wegovy

pharminent August 21, 2026
  • Clinical Data

Cancer vaccine win restores Wall Street’s faith in Moderna

pharminent August 20, 2026
  • Clinical Data

New Taiho, Cullian data heats up lung cancer drug battle

pharminent August 13, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.